APGE

84.54

1.50% 1.25

Handel nachbörslich: 84.54

Apogee Therapeutics Inc (APGE)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$83.29

Offen:

$83.88

24-Stunden-Volumen:

413.64K

Relative Volume:

0.46

Marktkapitalisierung:

$6.37B

Einnahmen:

Nettoeinkommen (Verlust:

$-255.84M

KGV:

-20.06

EPS:

-4.2149

Netto-Cashflow:

$-232.60M

1W Leistung:

+3.06%

1M Leistung:

+0.63%

6M Leistung:

+53.72%

1J Leistung:

+137.67%

1-Tages-Spanne:

$83.39

$85.03

1-Wochen-Bereich:

$80.52

$85.45

52-Wochen-Spanne:

$34.34

$95.31

Apogee Therapeutics Inc Stock (APGE) Company Profile

Firmenname

Apogee Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

650-394-5230

Adresse

221 CRESCENT ST., WALTHAM

Mitarbeiter

261

Twitter

Nächster Verdiensttermin

2026-05-11

Neueste SEC-Einreichungen

APGE's Discussions on Twitter

Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
APGE Apogee Therapeutics Inc	84.54	6.28B	0	-255.84M	-232.60M	-4.2149
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-18	Eingeleitet	Truist	Hold
2026-01-22	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2026-01-07	Eingeleitet	Wolfe Research	Peer Perform
2025-12-17	Eingeleitet	Stephens	Overweight
2025-12-10	Eingeleitet	Deutsche Bank	Buy
2025-11-03	Eingeleitet	Craig Hallum	Buy
2025-10-21	Eingeleitet	Mizuho	Outperform
2025-09-25	Eingeleitet	RBC Capital Mkts	Outperform
2025-07-07	Bestätigt	BTIG Research	Buy
2025-03-13	Eingeleitet	Citigroup	Buy
2024-11-25	Eingeleitet	Canaccord Genuity	Buy
2024-05-10	Eingeleitet	BofA Securities	Buy
2023-12-20	Eingeleitet	BTIG Research	Buy
2023-08-08	Eingeleitet	Guggenheim	Buy
2023-08-08	Eingeleitet	Jefferies	Buy
2023-08-08	Eingeleitet	Stifel	Buy
2023-08-08	Eingeleitet	TD Cowen	Outperform
2023-08-08	Eingeleitet	Wedbush	Outperform

Alle ansehen

Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten

04:25 AM

Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold - Stock Titan

04:25 AM

May 04, 2026

CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan

May 04, 2026

May 02, 2026

Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat

May 02, 2026

Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat

May 02, 2026

Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN

May 02, 2026

May 01, 2026

Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan

May 01, 2026

Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo

May 01, 2026

Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat

May 01, 2026

Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK

May 01, 2026

Rothschild Redburn initiates Apogee stock with buy on AD therapy By Investing.com - Investing.com India

May 01, 2026

Apr 29, 2026

Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN

Apr 29, 2026

APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN

Apr 29, 2026

Apogee Therapeutics (APGE) Study result Summary - Quartr

Apr 29, 2026

Apogee Therapeutics (APGE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr

Apr 29, 2026

Apr 27, 2026

Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough - HarianBasis.co

Apr 27, 2026